compani
post-elan model updat retir
po rais retir share higher forecast
updat model reflect recent complet exchang
updat account vitrakvi cancer bayer chang control new pharma-
sale forecast vs con ex-elan y/i similar prior
quarter expect trulic diabet taltz immunolog top-line growth
driver strong script trend rais estim drive
increas pharma out-year sale revenu ep forecast
vs con vs prior estimate respect within
mgmt guidanc rang reflect slight accret retir share
spin forecast op margin expans
time-frame assum posit op leverag key brand
trulic new po remain neutral skeptic share re-rat
premium multipl
preview trulic trend encourag
takeaway analysi iqvia us trulic growth remain strong
categori grow y/i trulic share
assum flat y/i price translat us trulic sale y/i versu
con us taltz q/q script growth view con sale
achiev even assum challeng gross-to-net emgal
migrain lli exit weekli cgrp share forecast sale base
paid rx ratio commentari revenu ratio increas verzenio
script growth in-lin est q/q exit weekli share
focu confer call
focu trulic anticip competit impact nvo oral semaglutid
recent file review leverag prioriti review voucher commentari
rewind ahead june ada present jardianc price outlook
class script growth strong y/i assum re-inclus
formulari may come cost us growth lag script estimate price
drag y/i verzenio miss our/con estim last quarter
note script indic q/q categori growth share gain
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
timestamp march edtcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani march
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough target
forecast pharma revenu vs first order consensu
pharma y/i mainli driven trulic diabet y/i taltz psoriasi
verzenio breast cancer discuss trend growth
product recent launch emgal
us trulic drive categori growth forecast us trulic sale
vs con take account y/i script growth
flat net price categori growth remain strong y/i
vs share us non-insulin market despit competitor
novo ozemp launch trulic expand categori share
wherea ozemp improv mainli gain share
verzenio script trend line consensu estim verzenio script grew
y/i q/q note script indic q/q categori
growth share gain compar
compani march
emgal move crpg share current share cgrp script
share new cgrp start nbrx
chart total prescript share cgrp biolog
chart new brand prescript nbrx share cgrp biolog
compani march
compani
price object po base blend averag discount
cash flow dcf multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani march
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani march
